The objective is to evaluate the influence of chemotherapy, either for auto-immune disease, either for carcinologic disease, on clinical and biological markers of ovarian reserve, for young patients, with normal reproductive functions.
The study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant chemotherapy for systemic lupus erythematosus (Group 1), breast cancer (Group 2) or Hodgkin disease (Group 3)to evaluate the clinical and biological markers of ovarian reserve. The follow-up will last 24 months for each patients with a visit before treatment, and at 3 months, 6 months, one year and two years after treatment. During this period, we will collect pre and post treatment clinical data,and biological data and ultrasonographic data such as antral follicle count which is a marker of ovarian follicle reserve.These data were not observed in current practice.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
19
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
AP-HP Hôpital Antoine Béclère
Clamart, France
AMH level and antral follicle count
Time frame: one year after the chemotherapy treatment
AMH level and antral follicle count at each visit
Time frame: 3 months, 6 months, and two years after the chemotherapy treatment
Hormonal status (Estradiol, LH, FSH and progesterone levels)
Time frame: 3 months, 6 months, and two years after the chemotherapy treatment
Menstrual cyclicity
Time frame: 3 months, 6 months, and two years after the chemotherapy treatment
pregnancy
Time frame: 3 months, 6 months, and two years after the chemotherapy treatment
infertility treatment if required
Time frame: 3 months, 6 months, and two years after the chemotherapy treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.